Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
6 reports, 2 independent
Updated Sep 28
Gone quiet
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.CEO Emily Leproust sold shares under a 10b5-1 plan; company listed on NASDAQ.1 source
Analyst firm set price targets for company; CEO sold shares due to tax withholding.1 source
Keep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
Twist Bioscience
Biotechnology company